Trogarzo to non-MDR HIV patients Last Thursday Taimed held its annual shareholder’s meeting at Taipei. In the meeting, President & CEO Dr. James Chang mentioned that recently he has had intensive discussion with TH top management about the marketing and promotion of Trogarzo. Dr. Chang said TH sales force is taking some new measures to speed up the penetration and expand the targeting market. One of which is trying to promote Trogarzo to non-MDR HIV patients who are suffering severe side-effects from oral drugs. I wonder if those non-MDR HIV patients taking Trogarzo can get reimbursement acceptance. Does anyone know? And do you think Trogarzo’s relatively mild side-effects will be appealing to quite a few non-MDR HIV patients?